Email this article HORMONE REFRACTORY PROSTATE CANCER AND ITS DEVELOPMENT DURING ANTIANDROGEN THERAPY
- Authors: Rakul S.A.1, Galimov R.D.1
-
Affiliations:
- Citi Hospital Forty, Saint Petersburg
- Issue: Vol 8, No 2 (2012)
- Pages: 87-91
- Section: PROSTATE CANCER
- Published: 30.06.2012
- URL: https://oncourology.abvpress.ru/oncur/article/view/345
- DOI: https://doi.org/10.17650/1726-9776-2012-8-2-87-91
- ID: 345
Cite item
Full Text
Abstract
Mechanisms of development of hormone refractory prostate cancer currently not fully understood.
Materials and methods: treatment results of 135 prostate cancer patients underwent subcapsular orchiectomy.
Results: hormone resistance registered at 38 (28.15%) patients, were sensitive to anti-androgenic therapy 97 (71.85%) patients. There are reliable differences between the probability of development of hormone refractory and the patient's age, disease stage and degree of tumor cell differentiation.
Conclusion: сlinical developed, laboratory and pathomorphological criteria, the use of which may reliably predict the likelihood of hormone refractory patients with prostate cancer on the background of antiandrogenic treatment.
About the authors
S. A. Rakul
Citi Hospital Forty, Saint Petersburg
Email: garustam@yandex.ru
Russian Federation
R. D. Galimov
Citi Hospital Forty, Saint Petersburg
Author for correspondence.
Email: garustam@yandex.ru
Russian Federation
References
Supplementary files
